Arbutus Biopharma Corp (ABUS): prezzo delle azioni e notizie

Home pageABUS • NASDAQ

Arbutus Biopharma Corp

4,37 $

16 mar, 15:09:14 GMT-4 · USD · NASDAQ · Disclaimer

Titolo azionarioTitolo quotato in USACon sede in USA

Chiusura precedente

4,26 $

Intervallo giornaliero

4,24 $ - 4,41 $

Intervallo annuale

2,71 $ - 5,10 $

Cap di mercato

839,49 Mln USD

Volume medio

2,67 Mln

Rapporto P/E

Dividendo/Prezzo

Borsa valori principale

NASDAQ

Notizie del mercato finanziario

CoinCentral

52 minuti fa

Abra Targets Nasdaq Listing in $750M SPAC Deal Amid Crypto Market Revival

Broadcom (AVGO) witnessing continued momentum in AI semiconductor segment

Large-format Grocery & General Merchandise Retailer Stocks Q4 Earnings Review: Target (NYSE:TGT) Shines

A rebound could be coming for the Dow, but the charts show it may be short lived

Apollo’s Torsten Slok: S&P 500 could see top 10 reach 50% weighting

Cyngn Inc. Announces $9.65 Million Registered Direct Offering, Priced at the Market Under Nasdaq Rules

CYN

1,68%

Informazioni

Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection. It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007. Wikipedia

CEO

William H. Collier

Fondazione

2007

Sede

Warminster, Pennsylvania
Stati Uniti

Sito web

arbutusbio.com

Dipendenti